TY - JOUR
T1 - Successful Recombinant Thrombomodulin Treatment for Thrombotic Microangiopathy After Liver Transplantation
T2 - A Case Report
AU - Motomura, Takashi
AU - Yoshizumi, T.
AU - Ohira, M.
AU - Mano, Yohei
AU - Toshima, T.
AU - Itoh, S.
AU - Harada, N.
AU - Harimoto, Norifumi
AU - Ikegami, Toru
AU - Soejima, Yuji
AU - Maehara, Yoshihiko
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/12
Y1 - 2017/12
N2 - Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare but severe complication after liver transplantation. In contrast to other thrombotic microangiopathies, treatment for TA-TMA has yet to be clarified. A 52-year-old male patient with liver cirrhosis due to hepatitis C underwent split liver transplantation from a deceased donor. His clinical course was without complication until 4 days after transplantation, when he experienced impaired consciousness, hemolytic anemia with fragmented erythrocytes, and marked thrombocytopenia. TA-TMA was diagnosed, and recombinant thrombomodulin was administered for 4 days. The patient's clinical symptoms and laboratory data rapidly improved. He has been followed up for 6 months and has not shown any complications. The pathogenesis of TA-TMA is endothelial damage in the vasculature. Recombinant thrombomodulin, an endothelial cell–protecting agent, is a promising new therapeutic choice for TA-TMA after liver transplantation.
AB - Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare but severe complication after liver transplantation. In contrast to other thrombotic microangiopathies, treatment for TA-TMA has yet to be clarified. A 52-year-old male patient with liver cirrhosis due to hepatitis C underwent split liver transplantation from a deceased donor. His clinical course was without complication until 4 days after transplantation, when he experienced impaired consciousness, hemolytic anemia with fragmented erythrocytes, and marked thrombocytopenia. TA-TMA was diagnosed, and recombinant thrombomodulin was administered for 4 days. The patient's clinical symptoms and laboratory data rapidly improved. He has been followed up for 6 months and has not shown any complications. The pathogenesis of TA-TMA is endothelial damage in the vasculature. Recombinant thrombomodulin, an endothelial cell–protecting agent, is a promising new therapeutic choice for TA-TMA after liver transplantation.
UR - http://www.scopus.com/inward/record.url?scp=85040767428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040767428&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2017.09.014
DO - 10.1016/j.transproceed.2017.09.014
M3 - Article
C2 - 29198692
AN - SCOPUS:85040767428
SN - 0041-1345
VL - 49
SP - 2409
EP - 2410
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 10
ER -
